Warner-Lambert Company LLC v Apotex Pty Ltd

Warner-Lambert Company LLC brought proceedings against Apotex Pty Ltd in the Federal Court of Australia, seeking interlocutory relief in relation to the supply of pregabalin, a pharmaceutical product used for the treatment of seizures. The central issue in the case was whether Apotex could lawfully supply pregabalin under certain circumstances, specifically when the product was not listed on the Australian Register of Therapeutic Goods (ARTG) for the indication of treating seizures. This was contested on the basis that such supply might contravene Australian laws governing the marketing and distribution of pharmaceutical products, particularly those under the Therapeutic Goods Act 1989 and related regulations.

The court had to determine whether Apotex's actions were within legal bounds, particularly considering the implications of supplying a product not registered for a specific indication under the ARTG, and the interplay between Commonwealth and state legislation in regulating the supply of prescription medicines. The key legal questions revolved around the interpretation of the Therapeutic Goods Act, the Australian Register of Therapeutic Goods, and the Poisons Standard, as well as the practicalities of pharmacists substituting generic products and the regulatory frameworks governing the Pharmaceutical Benefits Scheme (PBS).

The court found that Apotex's actions were permissible under the relevant legislation. It held that while pregabalin was not listed on the ARTG for the treatment of seizures, this did not preclude Apotex from supplying the product if the prescription was in compliance with the relevant Poisons Legislation and other legal requirements. The court emphasised the distinction between the listing of a product on the ARTG for a specific indication and the broader legal framework that allows for the supply of medicines, including off-label uses, provided they are prescribed in accordance with the Poisons Legislation. The court also acknowledged the legitimate business practices of generic suppliers marketing their products to pharmacists, aiming to substitute generic products where legally permissible.

The court dismissed Warner-Lambert Company LLC's application for interlocutory relief, thereby allowing Apotex to continue supplying pregabalin under the contested conditions. The court's decision underscored the importance of understanding the interplay between various legislative frameworks and the practical realities of pharmacy practice in Australia.